Please assess the completion status of the following clinical trial:

Trial Title: Conversion to Monotherapy Study With Keppra XR for Partial Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects 12 to 75 years of age.~* Subjects must have inadequately controlled partial onset epilepsy.~* Subjects must be experiencing 2 to 40 seizures per 4-week period while being maintained on one or two standard AED(s)~Exclusion Criteria:~* A history of status epilepticus in the 6 months preceding randomization.~* Significant medical, psychiatric or neurological illness.~* Intake of benzodiazepines on more than an occasional basis~* History of previous treatment with levetiracetam or sensitivity to levetiracetam.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Keppra XR 1000 mg/day (Type: EXPERIMENTAL): 1000 mg/day once daily for 18 weeks (administered as two levetiracetam XR tablets and two placebo tablets once daily)
- Keppra XR 2000 mg/day (Type: EXPERIMENTAL): 2000 mg/day once daily for 18 weeks (administered as four levetiracetam XR tablets once daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).